Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions: clinical outcomes at one year.

Paul Barragan, Jean Fajadet, Imad Sheiban, Patrick Serruys, Antonio Colombo, Ricardo Seabra-Gomes, Jean Jacques Goy, Stéphane Cook, Paolo Rubino, Thierry Lefèvre

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

AIMS: Recent studies of drug-eluting stents for unprotected left main coronary artery (LMCA) disease have been encouraging. We examined the performance of sirolimus-eluting stents (SES) for this indication. METHODS AND RESULTS: This retrospective study included 228 consecutive patients (mean age = 68 +/- 11 years, 80.6% men, 26.3% diabetics) who underwent implantation of SES for de novo LMCA stenoses. The mean additive and logistic EuroSCOREs were 5.2 +/- 3.9 and 8.2 +/- 13.2, respectively. The main objective of this study was to measure the rate of major adverse cardiac events (MACE), including death, myocardial infarction and target lesion revascularisation (TLR) at 12 months. Other objectives were to measure the rates of in-hospital MACE and 12-month TLR. Outcomes in 143 patients with (BIF+ group), versus 84 patients without (BIF-group) involvement of the bifurcation were compared. The pre-procedural percent diameter stenosis (%DS) was 60.1 +/- 11.2 in the BIF+ versus 54.7 +/- 12.2% in the BIF- group (p=0.008), and decreased to 18.0 +/- 9.7 and 13.9 +/- 11.3%, respectively (ns), after SES implant. The overall in-hospital MACE rate was 3.5%, and similar in both subgroups. The 1-year MACE rate was 14.5% overall, 16.8% in the BIF+ and 10.7% in the BIF- subgroup (ns). CONCLUSIONS: SES implants in high-risk patients with LMCA stenoses were associated with a low 1-year MACE rate. Stenting of the bifurcation was associated with significant increases in neither mortality nor 1-year MACE rate.

Original languageEnglish
Pages (from-to)262-270
Number of pages9
JournalEuroIntervention
Volume4
Issue number2
Publication statusPublished - Aug 2008

Fingerprint

Sirolimus
Stents
Coronary Vessels
Coronary Stenosis
Drug-Eluting Stents
Coronary Artery Disease
Pathologic Constriction
Retrospective Studies
Myocardial Infarction
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Barragan, P., Fajadet, J., Sheiban, I., Serruys, P., Colombo, A., Seabra-Gomes, R., ... Lefèvre, T. (2008). Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions: clinical outcomes at one year. EuroIntervention, 4(2), 262-270.

Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions : clinical outcomes at one year. / Barragan, Paul; Fajadet, Jean; Sheiban, Imad; Serruys, Patrick; Colombo, Antonio; Seabra-Gomes, Ricardo; Goy, Jean Jacques; Cook, Stéphane; Rubino, Paolo; Lefèvre, Thierry.

In: EuroIntervention, Vol. 4, No. 2, 08.2008, p. 262-270.

Research output: Contribution to journalArticle

Barragan, P, Fajadet, J, Sheiban, I, Serruys, P, Colombo, A, Seabra-Gomes, R, Goy, JJ, Cook, S, Rubino, P & Lefèvre, T 2008, 'Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions: clinical outcomes at one year.', EuroIntervention, vol. 4, no. 2, pp. 262-270.
Barragan, Paul ; Fajadet, Jean ; Sheiban, Imad ; Serruys, Patrick ; Colombo, Antonio ; Seabra-Gomes, Ricardo ; Goy, Jean Jacques ; Cook, Stéphane ; Rubino, Paolo ; Lefèvre, Thierry. / Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions : clinical outcomes at one year. In: EuroIntervention. 2008 ; Vol. 4, No. 2. pp. 262-270.
@article{29fe7ca3a9844d81a2e61485fe88f264,
title = "Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions: clinical outcomes at one year.",
abstract = "AIMS: Recent studies of drug-eluting stents for unprotected left main coronary artery (LMCA) disease have been encouraging. We examined the performance of sirolimus-eluting stents (SES) for this indication. METHODS AND RESULTS: This retrospective study included 228 consecutive patients (mean age = 68 +/- 11 years, 80.6{\%} men, 26.3{\%} diabetics) who underwent implantation of SES for de novo LMCA stenoses. The mean additive and logistic EuroSCOREs were 5.2 +/- 3.9 and 8.2 +/- 13.2, respectively. The main objective of this study was to measure the rate of major adverse cardiac events (MACE), including death, myocardial infarction and target lesion revascularisation (TLR) at 12 months. Other objectives were to measure the rates of in-hospital MACE and 12-month TLR. Outcomes in 143 patients with (BIF+ group), versus 84 patients without (BIF-group) involvement of the bifurcation were compared. The pre-procedural percent diameter stenosis ({\%}DS) was 60.1 +/- 11.2 in the BIF+ versus 54.7 +/- 12.2{\%} in the BIF- group (p=0.008), and decreased to 18.0 +/- 9.7 and 13.9 +/- 11.3{\%}, respectively (ns), after SES implant. The overall in-hospital MACE rate was 3.5{\%}, and similar in both subgroups. The 1-year MACE rate was 14.5{\%} overall, 16.8{\%} in the BIF+ and 10.7{\%} in the BIF- subgroup (ns). CONCLUSIONS: SES implants in high-risk patients with LMCA stenoses were associated with a low 1-year MACE rate. Stenting of the bifurcation was associated with significant increases in neither mortality nor 1-year MACE rate.",
author = "Paul Barragan and Jean Fajadet and Imad Sheiban and Patrick Serruys and Antonio Colombo and Ricardo Seabra-Gomes and Goy, {Jean Jacques} and St{\'e}phane Cook and Paolo Rubino and Thierry Lef{\`e}vre",
year = "2008",
month = "8",
language = "English",
volume = "4",
pages = "262--270",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "2",

}

TY - JOUR

T1 - Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions

T2 - clinical outcomes at one year.

AU - Barragan, Paul

AU - Fajadet, Jean

AU - Sheiban, Imad

AU - Serruys, Patrick

AU - Colombo, Antonio

AU - Seabra-Gomes, Ricardo

AU - Goy, Jean Jacques

AU - Cook, Stéphane

AU - Rubino, Paolo

AU - Lefèvre, Thierry

PY - 2008/8

Y1 - 2008/8

N2 - AIMS: Recent studies of drug-eluting stents for unprotected left main coronary artery (LMCA) disease have been encouraging. We examined the performance of sirolimus-eluting stents (SES) for this indication. METHODS AND RESULTS: This retrospective study included 228 consecutive patients (mean age = 68 +/- 11 years, 80.6% men, 26.3% diabetics) who underwent implantation of SES for de novo LMCA stenoses. The mean additive and logistic EuroSCOREs were 5.2 +/- 3.9 and 8.2 +/- 13.2, respectively. The main objective of this study was to measure the rate of major adverse cardiac events (MACE), including death, myocardial infarction and target lesion revascularisation (TLR) at 12 months. Other objectives were to measure the rates of in-hospital MACE and 12-month TLR. Outcomes in 143 patients with (BIF+ group), versus 84 patients without (BIF-group) involvement of the bifurcation were compared. The pre-procedural percent diameter stenosis (%DS) was 60.1 +/- 11.2 in the BIF+ versus 54.7 +/- 12.2% in the BIF- group (p=0.008), and decreased to 18.0 +/- 9.7 and 13.9 +/- 11.3%, respectively (ns), after SES implant. The overall in-hospital MACE rate was 3.5%, and similar in both subgroups. The 1-year MACE rate was 14.5% overall, 16.8% in the BIF+ and 10.7% in the BIF- subgroup (ns). CONCLUSIONS: SES implants in high-risk patients with LMCA stenoses were associated with a low 1-year MACE rate. Stenting of the bifurcation was associated with significant increases in neither mortality nor 1-year MACE rate.

AB - AIMS: Recent studies of drug-eluting stents for unprotected left main coronary artery (LMCA) disease have been encouraging. We examined the performance of sirolimus-eluting stents (SES) for this indication. METHODS AND RESULTS: This retrospective study included 228 consecutive patients (mean age = 68 +/- 11 years, 80.6% men, 26.3% diabetics) who underwent implantation of SES for de novo LMCA stenoses. The mean additive and logistic EuroSCOREs were 5.2 +/- 3.9 and 8.2 +/- 13.2, respectively. The main objective of this study was to measure the rate of major adverse cardiac events (MACE), including death, myocardial infarction and target lesion revascularisation (TLR) at 12 months. Other objectives were to measure the rates of in-hospital MACE and 12-month TLR. Outcomes in 143 patients with (BIF+ group), versus 84 patients without (BIF-group) involvement of the bifurcation were compared. The pre-procedural percent diameter stenosis (%DS) was 60.1 +/- 11.2 in the BIF+ versus 54.7 +/- 12.2% in the BIF- group (p=0.008), and decreased to 18.0 +/- 9.7 and 13.9 +/- 11.3%, respectively (ns), after SES implant. The overall in-hospital MACE rate was 3.5%, and similar in both subgroups. The 1-year MACE rate was 14.5% overall, 16.8% in the BIF+ and 10.7% in the BIF- subgroup (ns). CONCLUSIONS: SES implants in high-risk patients with LMCA stenoses were associated with a low 1-year MACE rate. Stenting of the bifurcation was associated with significant increases in neither mortality nor 1-year MACE rate.

UR - http://www.scopus.com/inward/record.url?scp=59049107524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59049107524&partnerID=8YFLogxK

M3 - Article

C2 - 19110793

AN - SCOPUS:59049107524

VL - 4

SP - 262

EP - 270

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 2

ER -